Company / CapEx per Share
Enliven Therapeutics, Inc. CapEx per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.00
FY2024
5-year range
$0.00 / $0.20
FY2020-FY2024
Trend
-77.7%
vs FY2023
Sector context
#171 of 192
Health Care
What the data says
Enliven Therapeutics, Inc.'s capex per share of $0.00 is lower than 89% of companies in the Health Care sector (FY2024). Declined from $0.20 to $0.00 over the past 2 years.
Based on SEC 10-K filings.
0.00 in FY2024 with a 5-year CAGR of -65.8%.
Declined from $0.20 to $0.00 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- +19.1%
- 5-Year CAGR
- -65.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 192This company $0.00 Sector average $2.46
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2024, capex per share decreased 77.7% year-over-year.
- Ranks #171 out of 192 companies in the Health Care sector.
- Peak capex per share was recorded in FY2019.
- Lowest capex per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.00 | -77.7% |
| FY2023 | $0.00 | -97.9% |
| FY2022 | $0.20 | +35259.7% |
| FY2021 | $0.00 | -57.1% |
| FY2020 | $0.00 | -99.4% |
| FY2019 | $0.20 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026